"Overall, these are promising early results, suggesting it may be possible to extend the honeymoon period in early Type 1 diabetes," said Josh Vieth, director of research for the nonprofit JDRF, which funds Type 1 diabetes research
Although ErbB4-specific agonists may offer a safer alternative than pan-ErbB activation, emerging evidence indicates that ErbB4 itself can function as an oncogene in various malignancies
Weight loss that supports the rest of your health The best weight-loss plan should support more than the number on the scale
doi: 10.1016/j.diabres.2020.108120, PMID: [DOI] [PubMed] [Google Scholar] 69.Heshmati J, Morvaridzadeh M, Maroufizadeh S, Akbari A, Yavari M, Amirinejad A, et al